找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Mechanical Circulatory Support for Advanced Heart Failure; A Texas Heart Instit Jeffrey A. Morgan,Andrew B. Civitello,O.H. Frazier Book 201

[復制鏈接]
樓主: 小巷
31#
發(fā)表于 2025-3-26 21:44:09 | 只看該作者
32#
發(fā)表于 2025-3-27 02:45:32 | 只看該作者
Who Is an Appropriate Candidate for Long-Term MCS?: The Art of Patient Selection,t is the leading cause of morbidity and mortality, with 50% mortality within 5?years of diagnosis [.]. Approximately less than 10% of this population will progress to advanced HF. These patients experience poor quality of life, frequent hospitalizations, and a 1-year mortality of 25–50% [2, 3]. Adva
33#
發(fā)表于 2025-3-27 07:46:50 | 只看該作者
34#
發(fā)表于 2025-3-27 09:29:15 | 只看該作者
35#
發(fā)表于 2025-3-27 13:59:16 | 只看該作者
36#
發(fā)表于 2025-3-27 20:53:43 | 只看該作者
LVAD Surgical Implant Technique: Infradiaphragmatic Approach, Despite the evolution to continuous flow devices, this technique has remained popular. However, an apical location can make patients vulnerable to arrhythmias and obstruction due to interaction with the ventricular septum. We developed a method for implanting the HeartMate II, HVAD, and HM3 LVAD al
37#
發(fā)表于 2025-3-27 22:24:23 | 只看該作者
38#
發(fā)表于 2025-3-28 03:09:25 | 只看該作者
39#
發(fā)表于 2025-3-28 08:08:09 | 只看該作者
Management of Fluid Balance and Perioperative Renal Complications,ure. Renal and liver dysfunctions often improve after left ventricular assist device placement, but complications in the postoperative period—especially hemodynamic instability, considerable blood loss and blood product replacement, prolonged cardiopulmonary bypass time, right heart failure, and inc
40#
發(fā)表于 2025-3-28 13:16:13 | 只看該作者
Chronic Management of Patients with Left Ventricular Assist Devices,g this event, the FDA approved implantable LVADs in 1994 as a bridge to transplantation. Due to a perpetual shortage of available organ donors for end-stage congestive heart failure (CHF) patients, durable LVAD implantation is now also used for destination therapy (DT) since 2002 after it received a
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學 Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經(jīng)驗總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學 Yale Uni. Stanford Uni.
QQ|Archiver|手機版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-25 21:32
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復 返回頂部 返回列表
内黄县| 金塔县| 恩施市| 闽清县| 陆良县| 伊宁县| 繁昌县| 云南省| 慈溪市| 改则县| 尼木县| 灵璧县| 合川市| 临汾市| 奉节县| 彰武县| 自治县| 安宁市| 西畴县| 夏津县| 拉萨市| 彰化县| 左云县| 临朐县| 潢川县| 西畴县| 梓潼县| 荔波县| 延长县| 定西市| 普洱| 苗栗县| 武功县| 水城县| 建始县| 浦县| 九江市| 老河口市| 东源县| 拉孜县| 大荔县|